5.06
0.59%
-0.03
After Hours:
5.04
-0.02
-0.40%
Waldencast plc stock is currently priced at $5.06, with a 24-hour trading volume of 87,278.
It has seen a -0.59% decreased in the last 24 hours and a -25.59% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.12 pivot point. If it approaches the $4.97 support level, significant changes may occur.
Previous Close:
$5.09
Open:
$5.2
24h Volume:
87,278
Market Cap:
$617.71M
Revenue:
-
Net Income/Loss:
$-11.05M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$2.18M
1W Performance:
-0.78%
1M Performance:
-25.59%
6M Performance:
-43.46%
1Y Performance:
+0.00%
Waldencast plc Stock (WALD) Company Profile
Name
Waldencast plc
Sector
Industry
Phone
917 546 6828
Address
10 Bank Street, Suite 560, White Plains
Waldencast plc Stock (WALD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Waldencast plc Stock (WALD) Latest News
Waldencast Announces Participation in CreatorIQ Connect Europe
GlobeNewswire Inc.
Waldencast Reports Fiscal Year 2023 Financial Results
GlobeNewswire Inc.
Waldencast Regains Compliance with Nasdaq Filing Requirements
GlobeNewswire Inc.
Waldencast Reports First Half 2023 Results
GlobeNewswire Inc.
Waldencast Receives Positive Nasdaq Listing Determination
GlobeNewswire Inc.
Waldencast Announces New “Creative Council” of Industry Pioneers and Disruptors
GlobeNewswire Inc.
Waldencast plc Stock (WALD) Financials Data
Waldencast plc (WALD) Net Income 2024
WALD net income (TTM) was -$11.05 million for the quarter ending June 30, 2022.
Waldencast plc (WALD) Cash Flow 2024
WALD recorded a free cash flow (TTM) of $2.18 million for the quarter ending June 30, 2022.
Waldencast plc (WALD) Earnings per Share 2024
WALD earnings per share (TTM) was -$0.2604 for the quarter ending June 30, 2022.
About Waldencast plc
Waldencast plc, a skincare company, develops, markets, and sells skin health products worldwide. The company offers approximately 200 cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force; and through distribution partners. The company was founded in 1988 and is based in White Plains, New York.
Cap:
|
Volume (24h):